Opinion|Videos|December 10, 2024
Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss how molecular testing is crucial in guiding treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the prevalence of mutations like BRAF, KRAS, MET, RET, and EGFR, and their impact on selecting targeted therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Davide Melisi, MD, PhD, discusses INCB161734’s mechanism of action and the DAWN-303 trial design in KRAS G12D-mutated pancreatic cancer.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement
Trending on OncLive
1
INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC
2
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
3
Fox Chase Cancer Center Researchers Identify Potential New Target for Pancreatic Cancer
4
Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
5